This study tests the hypothesis that the prevalence of severe clinical manifestations in Gaucher disease type 1 (GD1) patients at the time of treatment initiation has changed since alglucerase/ imiglucerase enzyme replacement therapy (ERT) was approved in the United States (US) in 1991.
hepatosplenomegaly, diverse patterns of skeletal disease, and growth retardation, and in the most severe cases, neurodegenerative disease.
The vast majority of cases are patients with GD type 1 (GD1) who lack the early-onset neurological disease that characterizes type 2 and type 3 disease. 3 GD1 is a chronic progressive disease. 4 The natural history of GD1 prior to the availability of an effective treatment was that of a devastating disease associated with a high incidence of splenectomy, bleeding complications, liver disease, painful and disabling skeletal disease due to fragility fractures, bone crisis and avascular osteonecrosis (AVN), pulmonary hypertension, malignancies, and premature death. [5] [6] [7] [8] [9] [10] Only symptomatic care was available in the form of blood transfusions and joint replacement surgery. Although splenectomy was frequently performed for symptomatic relief (pressure symptoms and cytopenia), it resulted in accelerated disease in bone and in other organs as well as life-threatening complications such as pulmonary hypertension. 5, 10, 11 Following proof of principle studies 12 and a pivotal clinical trial in 1991, 13 standard of care for GD1; imiglucerase has been shown to reverse many disease manifestations, including some bone pathologies, [15] [16] [17] and to reduce the risk of AVN. 18, 19 Since ERT became the standard of care in the 1990s, there appears to be a noticeable decline in the frequency of severe phenotypes typically encountered in the pre-ERT era. The purpose of this analysis is to confirm these clinical observations through a descriptive analysis of the disease manifestations of GD1 patients at the initiation of alglucerase/imiglucerase treatment during the two decades following the approval of alglucerase and imiglucerase. The
International Collaborative Gaucher Group (ICGG) Gaucher Registry (clinicaltrials.gov NCT00358943), initiated in 1991, offers an excellent instrument to assess temporal changes in the impact of the availability of ERT. Over the past quarter-century, the ICGG Gaucher Registry has captured phenotypic, genotypic, natural history and treatment response data in patients with GD from around the world. More than 6000 GD patients from over 60 countries have been enrolled in the Registry. 20 We analyzed clinical characteristics of symptomatic GD1 patients at the initiation of alglucerase/imiglucerase ERT in four approximately 5-year intervals over the first two decades after approval of alglucerase and imiglucerase, from 1991 to 2009. We focused in particular on whether the prevalence of splenectomy at the time of treatment initiation was declining, as this procedure has been associated with rapid progression to severe skeletal, pulmonary and hepatic manifestations as well as increased cancer risk. 
| Patient selection
As of March 04, 2016, GD1 patients were selected from the ICGG Gaucher Registry based on the following criteria: (1) enrolled from clinics and physician practices in the US, (2) began imiglucerase ("imiglucerase"
from here forward will refer to both alglucerase and imiglucerase treatment) ERT between January 1, 1991 and June 24, 2009 (inclusive), (3) had a known date of GD1 diagnosis and of imiglucerase initiation, (4) had reported splenectomy status and (5) Collapsing data from all four eras together, the prevalence of bone crisis, bone pain, and ischemic bone events was compared between splenectomized and non-splenectomized patients at baseline within each age group using the chi-square test or Fisher's exact test (for strata with small sample sizes). Within categories of age group and splenectomy status at initiation of imiglucerase, the chi-square test (or Fisher's exact test, when appropriate) was used to test differences in prevalence across the eras of each bone manifestation at baseline.
Hematologic endpoints (hemoglobin concentration, platelet count)
and liver volume at baseline were analyzed using analysis of variance (ANOVA) to compare mean values across the eras, stratified by age cohort and splenectomy status. Spleen volume for patients with intact spleens at treatment initiation was also analyzed using ANOVA to compare mean values across the eras stratified by age cohort.
All hypothesis tests were two-tailed with an alpha level of 0.05.
Statistical analyses were conducted using the SAS software version 9.2 (Cary, North Carolina).
| R E S U L T S 3.1 | Patients
As of March 04, 2016, 1427 (69.0%) of 2069 US GD1 patients in the ICGG Gaucher Registry met all inclusion and exclusion criteria. Most excluded patients were excluded because they were never reported as treated (n 5 327); 178 patients were excluded because they did not start imiglucerase within the specified time windows; 99 were excluded because of missing a GD1 diagnosis date; 12 were excluded because the first treatment was unknown; five were excluded because the first treatment was not imiglucerase; five patients were excluded for unknown imiglucerase initiation date; two patients were excluded for conflicting treatment initiation dates; 13 were excluded for missing date of splenectomy (if splenectomized) and one patient was excluded for missing splenectomy status.
The distributions of sex, age at GD1 diagnosis, age at imiglucerase initiation, splenectomy status before treatment initiation, and genotype by age cohort and treatment initiation era are presented in Table 1 . Mean age at diagnosis differed significantly across the eras for each of the three age groups (P < .05 for pediatric patients; P < .0001 for adults 18 to <50 years; P < .05 for adults 50 years) as did age at initiation of treatment for pediatric patients (P < .0001) ( Table 1) . Genotype frequency across the eras was significantly different for the adults 18 to <50 years (P < .0001). There appears to be a greater frequency of the N370S homozygous genotype in later eras for this age group (Table 1) . No statistically significant differences in genotype were present in the other two age groups.
| Prevalence of splenectomy
Of the 1427 patients starting ERT across all 4 eras, 360 (25.2%) patients had undergone splenectomy prior to the initiation of imiglucerase (Table 1) . Among the patients who had undergone splenectomy (379), the majority (360 patients, 95%) were splenectomized prior to treatment. The reduction in splenectomy prevalence pre-ERT treatment was striking. Both adult groups who started ERT in Era 1 had a high prevalence of splenectomy, with 43% of adults 18 to <50 years and 44% of adults 50 years having been splenectomized pre-ERT (Table 1) . In pediatric patients, approximately 20% of patients who started ERT in Era 1 were splenectomized (Table 1 ). Compared to Era 1, patients who started ERT in subsequent Eras 2, 3, and 4, had significantly lower prevalence of splenectomy at the time of initiation of treatment (Table 1 and Figure 1 ). The trend was most marked in the pediatric population in whom splenectomy at the time of treatment initiation virtually disappeared in Era 4 relative to Era 1 (0% vs. 19.8%, respectively). The majority of the splenectomized adult patients, even those who began ERT in the later eras, had been splenectomized prior to 1991 (Supporting Information Table S1 ).
| Bone manifestations
In each age group, there was a highly significant excess of key manifestations of bone disease (bone crisis, ischemic bone events, and bone pain) in splenectomized patients compared to patients with intact spleen (P < .0001, Supporting Information Figure S1 ) with data collapsed across all 4 treatment initiation eras. Further stratification of patients with and without spleen by treatment era revealed a significantly lower prevalence of bone crisis in pediatric patients with intact spleen with each successive era of ERT (P < .01) (Figure 2A ). We also found a decreasing prevalence of bone crisis in splenectomized (P < .05) and non-splenectomized (P < .05) adults 18 to <50 years of age in later eras than in the first era. There were no significant differences in adults 50 years of age across eras.
The results for ischemic bone events parallel those for bone crisis, with a lower prevalence of patients with ischemic bone events in later eras ( Figure 2B ). Decreasing prevalence of ischemic bone events with each successive era is significant in pediatric patients with intact spleens (P < .01) and splenectomized adults 18 to <50 years of age (P < .05). Very few patients who initiated therapy in childhood have been splenectomized and the proportion of splenectomized patients declines in later eras for adult patients (Table 1) , necessitating caution when interpreting results involving small numbers of patients.
In general, bone pain was reported by a large proportion of patients by the time of treatment initiation with no significant differences in prevalence of bone pain across the eras in any age cohort ( Figure 2C ). Data on prevalence of fractures and hip replacement by era, age group, and splenectomy status were too sparse for meaningful interpretation (data not shown).
| Indicators of splenic and hepatic involvement
Splenomegaly and hepatomegaly were evident prior to treatment initiation in all eras (Supporting Information Table S1 ). Spleen volumes differed across eras, with significantly lower mean volumes observed in later eras for children and adults 18 to <50 years (P < .01) (Supporting Information Figure S2 Panel A). For hepatomegaly, the difference across the eras did not reach significance for any group except the intact spleen adults 18 to <50 years of age cohort (P < .01, Supporting
Information Figure S2 Panel B).
In pediatric patients, >94% of non-splenectomized patients had moderate or severe splenomegaly in each era and >95% had moderate or severe hepatomegaly in each era (Supporting Information 
| Indicators of hematological disease
Overall there were no clinically meaningful differences in hemoglobin concentrations or platelet counts across the eras. Significant P-values (P < .05) were observed for hemoglobin concentration among nonsplenectomized and splenectomized adults 18 to <50 years, with slightly higher concentrations in later eras, and for platelet counts among non-splenectomized pediatric patients, with no apparent trend across eras (Supporting Information Figure S2 panels C and D, respectively). Anemia ranged from 18.8% to 61.1% across the eras and age groups with no discernable trend (Supporting Information Table S2 ).
Thrombocytopenia tended to be in the mild to moderate range; pediatric patients had the lowest prevalence of severe thrombocytopenia (Supporting Information Table S2 ).
FIG URE 1
The proportion of GD1 patients who were splenectomized prior to imiglucerase initiation by age group and era of imiglucerase initiation. ****P < .0001. P-values are from chi-square test. Abbreviations: GD1, Gaucher disease type 1
| Time interval between GD1 diagnosis and initiation of imiglucerase
The median time interval between GD1 diagnosis and initiation of treatment differed across eras (P < .0001 for pediatric patients and adults 18 to <50 years and P < .01 for adults 50 years), with the longest interval observed in Era 1 in all age groups (Figure 3 ).
| DISCUSSION
Until the introduction of alglucerase/imiglucerase ERT in the early 1990s, individual cohort studies of GD1 depicted generally devastating disease with high rates of splenectomies, disabling skeletal complications and premature deaths. 8, 10, 24 During two decades of ERT, clinicians have observed a remarkable transformation in the presenting phenotype of GD1. Our study is the first formal assessment of the changing spectrum of disease manifestations at the time of treatment initiation in the era of ERT. We focused our study on the US as imiglucerase ERT was first approved here, and we hoped our study cohort Our most clinically significant finding is the markedly diminished role of splenectomy in the management of GD1 since the introduction of ERT in 1991. In all age groups, the vast majority of pre-ERT splenectomies were performed prior to 1991 (Supporting Information Table S1 ). In the pediatric group, where the time interval between diagnosis and initiation of ERT showed a striking closure across the eras, splenectomies were completely eliminated by Era 4.
We saw a similar trend in the reduction in splenectomies in the adult cohorts, but a significant proportion of adult patients had undergone splenectomies sometime prior to ERT treatment even in Era 4. The Table S1 ). Although the ICGG Gaucher Registry does not capture indications for splenectomies, the collective experience of the authors suggest they were most likely performed for massive splenomegaly, pressure symptoms and cytopenia, with some patients having the procedure for misdiagnosis of hematological malignancy.
A higher frequency of signature bone events (bone crisis, ischemic bone events, and bone pain) in splenectomized patients compared to non-splenectomized patients was observed in our large cohort of US ICGG Gaucher Registry patients in keeping with smaller single-center studies. 2, 5, 6, 19, 25 Without GD1-specific treatment, splenectomy removes a reservoir organ for the storage of the primary substrate glucosylceramide and secondary pathogenic substrates such as glucosylsphingosine, 26 leading to accelerated accumulation of Gaucher cells at other sites, which in turn accelerates bone disease, 5,25 liver disease, 27 pulmonary hypertension, 28 marrow disease causing bone marrow failure, 29 and immune alterations and comorbidities. 30 Thus, a consensus conference of leading Gaucher disease physician experts have determined that a major goal in management of GD1 is to prevent splenectomy through timely initiation of ERT. 11, 31 With widely available, non-invasive, reliable testing for GD, diagnostic splenectomy is strongly contraindicated and palliative total splenectomy is not recommended except under life-threatening circumstances such as uncontrollable bleeding or splenic rupture. 32 The concept that treatment instituted after splenectomy may avert postsplenectomy complications is questionable in light of studies showing that postsplenectomy patients treated with ERT continue nevertheless to suffer new ischemic bone events. 19, 33 It is therefore gratifying to confirm that with the advent of ERT, the number of splenectomized GD1 patients initiating treatment has decreased dramatically. Our study suggests management of GD1 patients in the US is making steady progress towards timely initiation of ERT to prevent the need for splenectomy. The reduced need for splenectomy, in the era of ERT has also been reported in a study of 99 Dutch patients.
11
Further studies should examine the temporal trends with respect to splenectomy in GD1 and define the rare indications for splenectomy in the era of ERT.
A statistically significant decrease in the prevalence of bone crisis and ischemic bone events was observed across the eras in spleen-intact pediatric patients and a similar trend occurred in some adult patients as well (Figure 2A,B) . This important finding underscores that splenectomy is not the only determinant of bone crises and ischemic bone events. Bone manifestations can occur in the setting of intact spleen and their prevalence may be reduced by early initiation of ERT. 19 Consistent with the latter concept, we found that the median interval between the age at diagnosis and the age at beginning imiglucerase treatment decreased over the eras (Figure 3 ).
This effect was observed most clearly in pediatric patients who began
Median interval between age at diagnosis and age at imiglucerase initiation by age group and era of imiglucerase initiation. **P < .01; ****P < .0001. P-values were derived from Kruskal-Wallis test ERT almost simultaneously with diagnosis in later eras relative to earlier eras when there was significant delay between diagnosis and treatment initiation. This salutary development of timely institution of treatment should decrease the risk of AVN, 19 enhance bone development and growth in children, prevent delayed puberty, [34] [35] [36] and increase the years of improved quality of life for patients with GD1. 37 One of the most interesting findings of our study was that a his- GBA gene genotype frequencies in patient cohorts showed the expected distribution in Era 1, with a lower prevalence of N370S homozygosity in pediatric patients (15%), rising to 28% in adults 18 to < 50 years and 57% in adults 50 years (Table 1) , and with reciprocal trends for N370S/other genotypes. The comparison of genotype frequencies across the eras within each age group did not find any significant differences with the exception of the adults 18 to <50 years of age in whom there is an increased prevalence of N370S homozygosity in later eras.
While generally N370S homozygosity is associated with milder disease, several studies have shown many of these patients present with severe disease manifestations even in childhood. [39] [40] [41] [42] Our study does not address the issue of N370S homozygous or other patients identified through newborn screening and whether there is role for ERT in the prevention of disease manifestations. Our study is entirely focused on patients with variable degrees of symptomatic disease with visceral, hematological and skeletal manifestations including bone pain.
Current treatment algorithms and third party payor guidelines largely presuppose that patients will have advanced disease. These guidelines may need to be revisited as evidence accrues that early treatment before the onset of irreversible manifestations may improve long-term, patient-centered outcomes and may prevent the irreversible morbidity that characterized GD1 patients in the pre-ERT era at great cost to the quality and quantity of their lives. 18, 19, 34 Whether early institution of treatment can avert some of the late-onset complications of GD1 and reduce the incidence of hematologic malignancies such as multiple myeloma, for which Gaucher patients have a 5-60-fold increased risk, 43, 44 needs further study.
Although our study is one of largest cohorts reported, the study has some limitations common to any observational registry study.
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